Search

Your search keyword '"Nutlin-3a"' showing total 130 results

Search Constraints

Start Over You searched for: Descriptor "Nutlin-3a" Remove constraint Descriptor: "Nutlin-3a" Search Limiters Full Text Remove constraint Search Limiters: Full Text
130 results on '"Nutlin-3a"'

Search Results

1. Role of Annexin 7 (ANXA7) as a Tumor Suppressor and a Regulator of Drug Resistance in Thyroid Cancer.

2. Enhanced Anti-Melanoma Activity of Nutlin-3a Delivered via Ethosomes: Targeting p53-Mediated Apoptosis in HT144 Cells.

Catalog

Books, media, physical & digital resources

3. Enzymatic Desymmetrisation of Prochiral meso -1,2-Disubstituted-1,2-Diaminoethane for the Synthesis of Key Enantioenriched (−)-Nutlin-3 Precursor.

4. Photoacoustic features of nylon-11 nanoparticles for breast cancer imaging, and their modification with trastuzumab, sorafenib, and nutlin-3a for theranostic applications

5. Microfluidic Fabricated Liposomes for Nutlin-3a Ocular Delivery as Potential Candidate for Proliferative Vitreoretinal Diseases Treatment

6. Nutlin-3a regulates mouse adipose function by inhibition of CIDEC expression

7. New Insights into Chemoresistance Mediated by Mdm2 Inhibitors: The Benefits of Targeted Therapy over Common Cytostatics.

8. Nutlin-3a 通过抑制 CIDEC 的表达调控小鼠脂肪功能.

9. Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2

10. Suppression of p53 response by targeting p53-Mediator binding with a stapled peptide

11. Enhanced Anti-Melanoma Activity of Nutlin-3a Delivered via Ethosomes: Targeting p53-Mediated Apoptosis in HT144 Cells

12. Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2.

13. Delineating mechanisms which underlie differential cell fates induced by p53 activation and HDAC inhibition in colorectal cancer

14. Enzymatic Desymmetrisation of Prochiral meso-1,2-Disubstituted-1,2-Diaminoethane for the Synthesis of Key Enantioenriched (−)-Nutlin-3 Precursor

15. New Insights into Chemoresistance Mediated by Mdm2 Inhibitors: The Benefits of Targeted Therapy over Common Cytostatics

16. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

17. Ultrasound-responsive nutlin-loaded nanoparticles for combined chemotherapy and piezoelectric treatment of glioblastoma cells.

18. Modulation of anti-angiogenic activity using ultrasound-activated nutlin-loaded piezoelectric nanovectors

19. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

21. Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53

22. Nutlin‐3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation

23. Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways

24. Nutlin-loaded magnetic solid lipid nanoparticles for targeted glioblastoma treatment.

25. Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a.

26. MDM2 antagonist nutlin‐3a sensitizes tumors to V‐ATPase inhibition

27. Ultrasound-responsive nutlin-loaded nanoparticles for combined chemotherapy and piezoelectric treatment of glioblastoma cells

28. Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma

29. Expression of miR-34a in T-Cells Infected by Human T-Lymphotropic Virus 1

30. DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a.

31. Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death.

32. Nutlin‐3a as a novel anticancer agent for adrenocortical carcinoma with <italic>CTNNB1</italic> mutation.

33. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis.

34. Targeting Cell Cycle Facilitates E1A-Independent Adenoviral Replication.

35. P53-MDM2 PATHWAY: EVIDENCES FOR A NEW TARGETED THERAPEUTIC APPROACH IN B-ACUTE LYMPHOBLASTIC LEUKEMIA

36. Colorectal cancer triple co-culture spheroid model to assess the biocompatibility and anticancer properties of polymeric nanoparticles

37. Lipid - protein interactions : from signal transduction to drug delivery

38. P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia.

39. MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition.

40. Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma

41. Characterising Mutational Spectra of Carcinogens in the Tumour Suppressor Gene Using Human Knock-in (Hupki) Mouse Embryo Fibroblasts

42. Characterising Mutational Spectra of Carcinogens in the Tumour Suppressor Gene Using Human Knock-in (Hupki) Mouse Embryo Fibroblasts

43. Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53.

44. Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance.

45. Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy.

46. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.

47. Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line

48. Establishment of drug-resistant cell lines under the treatment with chemicals acting through different mechanisms.

49. Nutlin-loaded magnetic solid lipid nanoparticles for targeted glioblastoma treatment

50. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals